Table 2.
Summary of the ten gene signatures selected for this analysis, in rank order from lowest to highest W/T.
| Signature | Development Site(s) | Number of Genes* | Number of Probe Sets† | Signature Score (Median, range) | W/T by Number of Biopsies |
||||
|---|---|---|---|---|---|---|---|---|---|
| W/T1 | W/T2 | W/T3 | W/T4 | W/T5 | |||||
| Fjeldbo [31] | Cervix | 6 (4) | 10 (6) | 7.87 (6.73–10.17) | 0.21 | 0.12 | 0.08 | 0.06 | 0.05 |
| Hu [32] | Breast | 15 (13) | 26 (20) | 7.44 (6.51–8.67) | 0.26 | 0.15 | 0.10 | 0.08 | 0.06 |
| Toustrup [24] | HN | 15 (15) | 37 (25) | 8.68 (7.19–9.63) | 0.28 | 0.17 | 0.12 | 0.09 | 0.07 |
| Halle [30] | Cervix | 31 (28) | 66 (43) | 0.01 (-0.52–0.49) | 0.29 | 0.17 | 0.12 | 0.09 | 0.08 |
| Buffa [26] | HN Breast |
51 (51) | 51 (51) | 8.77 (8.14–9.39) | 0.31 | 0.18 | 0.13 | 0.10 | 0.08 |
| Ghazoui [28] | Breast | 70 (68) | 136 (113) | 8.77 (8.25–9.15) | 0.33 | 0.20 | 0.14 | 0.11 | 0.09 |
| Betts [20], [29] | HN | 26 (25) | 58 (50) | 8.41 (7.54–8.84) | 0.40 | 0.25 | 0.18 | 0.14 | 0.12 |
| Winter [27] | HN | 99 (92) | 126 (119) | 7.96 (7.42–8.76) | 0.41 | 0.26 | 0.19 | 0.15 | 0.12 |
| Ragnum [33] | Prostate | 32 (28) | 61 (49) | 0.02 (-0.61–0.52) | 0.44 | 0.28 | 0.21 | 0.17 | 0.14 |
| Yang [34] | Prostate | 28 (26) | 66 (50) | 0.19 (-1.41–1.71) | 0.45 | 0.29 | 0.21 | 0.17 | 0.14 |
W/T1–5 Within-tumor variance divided by the Total sample variance when one to five biopsies are available. Lower W/T1–5 implies greater capacity of one or multiple biopsies to discriminate among tumors in the face of heterogeneity.
*
Number of genes in the original signatures vs. number of genes found in the Affymetrix array and used in this analysis.
†
Total number of probe sets vs. number of probe sets found in the Affymetrix array and used in this analysis.